Articles
By Wayne Kuznar
The results of the phase 3 OPTIMISMM clinical trial showed a 39% risk reduction in disease progression or death with pomalidomide, bortezomib, and low-dose dexamethasone compared with bortezomib and low-dose dexamethasone alone. Read More ›
The drug affordability ratings in the National Comprehensive Cancer Network Evidence Blocks are inconsistent with real-world total episode-of-care costs, according to Scott D. Ramsey, MD, PhD, Director, Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA. Read More ›
The investigational LOXO-292, a potent and highly selective RET kinase inhibitor, has demonstrated robust and durable antitumor activity against RET-activating fusions and mutations, and has shown promising efficacy in patients with solid tumors and RET mutations. Read More ›
The second-generation chimeric antigen receptor (CAR) T-cell therapy, bb2121, engineered to target B-cell maturation antigen, a protein on the surface of certain myeloma cells, displayed continuing efficacy and safety in an update of a phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.
Read More ›
Navigating through the oncology landscape has become increasingly challenging. As a result, it is imperative for oncology practices today to stay abreast of the changes occurring in the field to succeed. Read More ›
PD-L1 expression is a rational biomarker to predict response to PD-1/PD-L1 ICI therapy, and has been studied extensively in clinical trials. A recurring theme emerging from available clinical data is that high levels of tumor cell membrane PD-L1 expression correlate with better outcomes with PD-1/PD-L1 blockade. Read More ›
Testing in Patients with Cancer Clearly, immunotherapy has come of age in multiple tumor types, as described in the main article in this publication. The question now is how to develop more personalized immunotherapy and use biomarkers to identify patients most likely to benefit from this therapy. Read More ›
In the main article of this publication, the current state of programmed-cell death-1 and programmed-cell death ligand-1 (PD-L1) testing, evasion by tumors of the immune system, and the study and use of immune checkpoint inhibitors across multiple tumor types are expertly summarized. Read More ›
By Wayne Kuznar
In the FDA’s dynamic regulatory environment, the patient voice has been adopted and end points for clinical trials have evolved from overall survival to other efficacy measures. “Having multiple drugs is a good thing. Many are approved on nonsurvival end points, and they have transformed the diseases,” said Richard Pazdur, MD. Read More ›
By Wayne Kuznar
The NCCN’s first guideline for side effects from immunotherapy recognizes a new spectrum of events in patients who are receiving immune checkpoint inhibitor therapy. Read More ›